(877) 284-6600
Local (816) 221-6600

Biomet

The failure rate for metal hips in general is staggering, causing the FDA to create a panel of experts to study the problem on a larger scale. The Biomet M2a Magnum is one of several faulty metal-on-metal hip implant systems and in February 2015 the company issued a hazard alert for M2a Hip Implants.

Did You Miss the Biomet Hip Settlement Deadline?

The deadline to file a claim in court was on or before June 13, 2014. What you need to know is that the Biomet settlement offer only applies to those who have already had hip revision surgery. Biomet’s settlement agreement doesn’t include those who currently have a Magnum M2a hip implant.

Nash & Franciskato Law Firm is accepting cases that do not qualify for the settlement, which may be because you missed the deadline or because you have not yet had revision surgery. While you may not be able to participate in the settlement program, you still may have a case.

Contact us immediately to discuss your situation.


News Update on Biomet M2a Magnum Cases

Discovery Motion Granted on Biomet M2a Magnum Hip Replacement Cases
October 26, 2015. We are co-counsel with Maglio Christopher & Toale, PA on several M2a Magnum hip replacement cases that allege defects in the system. When a dispute arose over discovery requests asking for information regarding medical device report complaints on another device considered to be “substantially similar,” Magistrate Judge Deborah Bailey recommended the court grant our discovery motion.

Read the Full Post

M2a Magnum Metal-on-Metal Hip Litigation, St. Louis, MO
On August 25, 2017, Elizabeth and Ronald Sones filed a complaint against Zimmer Biomet Holdings Inc. (the maker of the magnum systems) alleging that the defendants failed their duty to use reasonable care in the design, manufacture, promotion, marketing, sales, supply, distribution and service of magnum systems. Nash & Franciskato is co-counsel with Maglio Christopher & Toale, PA on this case.

Read the Full Post

Our knowledgeable staff is available to answer your questions at (877) 284-6600.


Biomet Issues “Hazard Alert” for M2a Hip Implants in Australia

In February 2015, Biomet issued a hazard alert for its M2a range of acetabular and femoral head components when used in metal-on-metal (MoM) total hip replacement implants.

An analysis of the Australian Orthopaedic Association’s National Joint Replacement Registry data shows MoM hip implants using these components have higher than expected revision rates.

While Biomet has stopped the supply and sales of its M2a hip replacement components and cancelled them from the Australian Register of Therapeutic Goods, the company STILL sells and distributes these same components in the United States.

May 3, 2016 update: Zimmer Biomet issued a voluntary field safety corrective action for its M2a 38mm metal-on-metal hips warning European surgeons of problems with the device. Even though there are thousands of patients in the US with the same device, no such warnings have been issued here.


Biomet M2a Magnum Hip Implants

Patients with the Biomet M2a Magnum have reported problems with metal debris where the cup and the head rub together. This is called cobalt chromium poisoning and is linked to:

  • Tissue death
  • Higher than normal levels of metal in the blood
  • Hip pain
  • Loosening of the joint
  • Trouble walking
  • Revision surgery to replace the failed Biomet metal on metal hip

Reports suggest that Biomet was aware of the medical dangers associated with the implant. Rather than take it off the market, Biomet advertises the product as having a 99.2% success rate, a safer alternative to other products.

Titanium Poisoning in Biomet M2a Magnum Hip Systems

Unlike other metal on metal hips, part of the Biomet M2a Magnum hip is made out of titanium, adding another complication for people with this hip implant. Patients should get blood tests for titanium levels as well as the cobalt and chromium testing. Side effects from titanium poisoning are similar to those associated with cobalt and chromium metal toxicity in the body.


Considering a Revision Surgery?

If you are planning to have revision surgery for your Biomet M2a Magnum hip implant, talk with a lawyer first. It is essential to take possession of the implant as soon as it is removed to preserve it as evidence for your case. Pathology specimens will also be needed to document the amount and effect of the metal debris.

Defective medical device lawsuits are complicated. The experienced attorneys at Nash & Franciskato Law Firm will help you build a case to obtain the compensation you deserve.

Questions? Contact us to discuss your situation at (877) 284-6600.


Proven Results

We are a leading national law firm in the area of hip replacement litigation. Our attorneys have extensive experience handling hip replacement and knee replacement lawsuits, obtaining over $50 million in Collective Settlements involving defective knee and hip replacements.

More Case Results


Receive a Free Evaluation from Experienced Hip Replacement Attorneys

If you were implanted with a defective Biomet metal-on-metal hip replacement system that requires hip revision surgery, contact us today for a free, no-obligation case evaluation.

Contact Us


FAQ

What do I need to know about the Biomet M2a Magnum Settlement?
Q
A

A quick overview of the settlement includes:

  • Base compensation award of $200,000 if your hip was revised more than 180 days after it was implanted.
  • Biomet can add or deduct money from the $200,000 compensation amount depending on:
    • The type of M2a system
    • The time frame of when it was implanted or revised
    • The materials used in the implant
  • Your attorney can argue for Enhanced Payments if he or she believes there is “good cause.”
  • Biomet can contest your case and reduce the amount paid out if it believes there is “good cause.”
  • Non-revision cases will be dismissed from the settlement.
  • The statute of limitations is triggered by the date of your revision.
What is a hazard alert?
Q
A

A hazard alert is information issued to health professionals about issues or deficiencies relating to an implanted medical device and advice about ongoing management of patients.